-
Genetic variants of CYP2C9/VKORC1 (Montrer VKORC1 Protéines) and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement.
-
CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05).
-
polymorphisms c.98T>C in the UGT1A9 (Montrer UGT1A9 Protéines) and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol
-
Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR (Montrer INSR Protéines)) in the therapeutic range (TTR (Montrer TTR Protéines)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 (Montrer VKORC1 Protéines) c.-1693G>A polymorphism
-
Three SNPs (CYP2C9 *2, *3 and VKORC1 (Montrer VKORC1 Protéines) c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe.
-
This study was aimed to describe the distribution of CYP2C9 and CYP2C19 (Montrer CYP2C19 Protéines) alleles and haplotypes in four Mestizo populations from Western Mexico. Frequencies ranged from 2.2-3.0% and 4.8-8.9% for CYP2C9*3 and CYP2C9*2 alleles, respectively, and 5.4-12.0% for CYP2C19 (Montrer CYP2C19 Protéines)*2, whereas the CYP2C19 (Montrer CYP2C19 Protéines)*3 allele was not found.
-
CYP2C9 IVS8-109 T carriers showed significantly higher dose-corrected phenoytoin blood concentrations and this allele was found in a higher frequency in epileptic patients with supratherapeutic phenytoin levels.
-
Med25 (Montrer MED9 Protéines), a variable member of the Mediator complex, is a coactivator of ligand-activated ERalpha (Montrer ESR1 Protéines) that interacts with ERalpha (Montrer ESR1 Protéines) through its C-terminal LXXLL motif after BPA (Montrer DST Protéines) exposure, and is functionally involved in BPA (Montrer DST Protéines)-induced transcriptional regulation of CYP2C9 expression and enzyme activity.
-
We conclude that CYP2C9/2C19 genotype is not relevant for variability in valproic acid exposure.
-
Our results show that anticoagulated patients have a high risk of adverse events if they are carriers of 1 or more genetic polymorphisms in the VKORC1 (Montrer VKORC1 Protéines) (rs9923231) and CYP2C9 (rs1799853 and rs1057910) genes.
